product name Piroxicam
Description: Piroxicam (also known as CP 16171) is a non-selective COX inhibitor, which is mainly used in the treatment of rheumatoid and osteoarthritis. As a COX-1 and COX-2 inhibitor, Piroxicam is an effective and potent inhibitor of prostaglandin synthesis. Studies show that Piroxicam blocks release of platelet ADP, and inhibits COX-1 more potently than COX-2.
References: J Neurochem. 2001 Jan;76(2):480-9; Carcinogenesis. 1997 Oct;18(10):1921-30.
331.35
Formula
C15H13N3O4S
CAS No.
36322-90-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 66 mg/mL (199.2 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
CP 16171
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19407723
| In Vitro |
In vitro activity: Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. Piroxicam and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats. Piroxicam increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. Piroxicam up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis. Piroxicam combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats. Piroxicam inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and Piroxicam does not have any direct cytotoxic effects in vitro. Piroxicam also binds strongly to plasma proteins and Piroxicam could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. Piroxicam prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats. |
| Animal model | |
| Formulation & Dosage | |
| References | J Neurochem. 2001 Jan;76(2):480-9; Carcinogenesis. 1997 Oct;18(10):1921-30. |
